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Background. In multiple sclerosis (MS), symptom management and improved health-related quality of life (HrQOL) may be
modified by smoking.Objective. To evaluate the extent to which smoking is associated with worsened health outcomes andHrQOL
for postmenopausal women with MS.Methods. We identified 251 Women’s Health Initiative Observational Study participants with
a self-reported MS diagnosis. Using a linear model, we estimated changes from baseline to 3 years for activities of daily living,
total metabolic equivalent tasks (MET) hours per week, mental and physical component scales (MCS, PCS) of the SF-36, and
menopausal symptoms adjusting for years sincemenopause and other confounders.Results. Nine percentwere current and 50%past
smokers. Age at smoking initiationwas associated with significant changes inMCS duringmenopause. PCS scores were unchanged.
While women who had ever smoked experienced an increase in physical activity during menopause, the physical activity levels of
women who never smoked declined. Residual confounding may explain this finding. Smoking was not associated with change in
menopausal symptoms during the 3-year follow-up. Conclusion. Smoking was not associated with health outcomes among post-
menopausal women with MS.
1. Introduction
Multiple sclerosis (MS) is a chronic disease of the cen-
tral nervous system with symptoms that impact health-
related quality of life (HrQOL) [1, 2]. MS disproportionately
affects more women than men [3]. The extent to which the
menopausal transition in women worsens MS symptoms
remains largely unexplored. Previous studies have addressed
symptommanagement inMS throughmodifiable risk factors
such as smoking [4]. Forty percent [5, 6] of women with MS
are current smokers, yet how smoking affects MS outcomes
after menopause is unknown.
In both menopausal and postmenopausal women, cur-
rent smokers report increased odds of vasomotor symptoms,
hot flashes, forgetfulness [7], and worsened HrQOL [8]. In
MS, smoking has been linked to increased incidence [6]
and faster MS progression [5, 9] leading to worse health
outcomes [10]. More than 37 million women are approaching
or experiencing menopause [11] in the aging U.S. population
[12].This underscores the need for greater focus on symptom
management for women with MS during the menopausal
transition and beyond. Using a multicenter prospective study
of U.S. postmenopausal women, we aimed to evaluate the
extent to which health outcomes including health-related
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quality of life and indicators of physical functioning are
worsened for women with MS who currently smoke or
previously smoked relative to women with MS who never
smoked.
2. Materials and Methods
TheVirginia CommonwealthUniversity Institutional Review
Board approved this study.
2.1. Participants. The Women’s Health Initiative Observa-
tional Study (WHI-OS), sponsored by the National Institutes
of Health and the National Heart, Lung, and Blood Institute,
followed 93,676 racially diverse women aged 50 to 79 years
and recruited from 40 clinical centers throughout the U.S.
[13]. Women were eligible for participation in theWHI-OS if
they were postmenopausal, not enrolled in other WHI clini-
cal trials, and unlikely to relocate or die within 3 years. Pro-
tocols for WHI-OS were reviewed and approved by human
subjects review committees at participating institutions [14].
Participants for the current study were included if they
reported “yes” to the question “Has a doctor ever told you
you had MS?” Analyses included 251 WHI-OS participants
who completed baseline and year three assessments and had
complete information on smoking history.
2.2. Determination of Smoking Status. Smoking status was
determined at baseline using the following questions: “Dur-
ing your entire life, have you smoked at least 100 cigarettes?”
and “Do you smoke cigarettes now?” The responses to these
questions were combined to classify women as current, past,
or never smokers. For women who reported ever having
smoked, we classified women according to their age at
smoking initiation (<20 years, 20–24 years, and ≥25 years),
the number of cigarettes smoked per day (<15/day, ≥15/day),
and the number of years smoked regularly (<30, ≥30 years).
Past smokers were asked age at cessation and classified
as <40 years, ≥40 years. Calculated by the WHI Clinical
Coordinating Center, the number of smoking pack-years [15]
was categorized as <10, 10–29, and ≥30 pack-years.
2.3. Outcome Ascertainment. We evaluated HrQOL, meno-
pausal symptoms, and indicators of physical functioning
and activity measures. HrQOL was measured using the
RAND 36-item health survey (SF-36) [16] which has been
validated in MS patients [17]. We calculated the mental
component score (MCS) and the physical component score
(PCS), each ranging from 0 (lower health) to 100 points
(better health) with 50 representing the mean score in
the general population. Activities of daily living (ADLs)
(modified from the original Katz et al. [18] index) consisted
of four separate items regarding ability to eat, ability to
get in and out of bed, dress, and/or take a bath on her
own. Each item had three possible values (1 = without help,
2 = some help, and 3 = completely unable). For baseline
and year 3, scores (ranging from 4 to 12) were summed to
represent overall ADLs with a lower score indicating better
health. BaselineADL scores were subtracted from year 3ADL
scores so that a positive change score represented a decline
in ADLs. Physical activity was computed from self-reported
energy expenditures for recreational activities, including
walking and other mild/moderate/strenuous activities (total
metabolic equivalent tasks (MET) hours/week). Calculated
MET hours per week are comparable to physical activity
diaries [19]. Baseline scores were subtracted from year 3
scores such that a positive change score indicated an increase
in physical activity.
Our focus was on menopausal symptoms, rather than
neurological symptoms. Based on the Postmenopausal Estro-
gen/Progestin Interventions symptom tool [20], we con-
sidered the following items as menopausal symptoms: for-
getfulness, difficulty in concentrating, mood swings, joint
pain or stiffness, headaches or migraines, breast tenderness,
increased or decreased appetite, hot flashes, night sweats,
vaginal/genital irritation, and vaginal/genital dryness. Par-
ticipants were asked how bothersome each symptom was
in the past four weeks (0 = did not occur, 1 = mild, 2 =
moderate, and 3 = severe). For each symptom, we created
a binary variable coded as 0 = did not occur and 1 =
symptom occurred (mild, moderate, and severe). At baseline
and year 3, a summary measure was constructed by adding
the number of symptoms reported (minimum score possible:
0; maximum score possible: 12). We treated the outcome as
a continuous variable by subtracting the baseline sum from
year 3 summary measure.
2.4. Potential Confounders. Potential confounders consid-
ered included age, education, race/ethnicity, years since
menopause, alcohol use, body mass index (BMI), depression,
menopausal hormone therapy (MHT) use, and vitamin D
intake. Years since menopause were calculated as the dif-
ference between the youngest reported age when menses
ceased (age when participant experienced last menstrua-
tion, oophorectomy, or initiated MHT) and age at base-
line. Baseline alcohol use was assessed using the Food
Frequency Questionnaire (FFQ) and categorized as never,
past, and current use. BMI was calculated in kg/m2 units
from heights and weights measured with calibrated balances
and stadiometers (<18.5 kg/m2, 18.5 kg/m2, and < 25 kg/m2;
25 kg/m2 to 30 kg/m2; and ≥ 30 kg/m2). MHT (unopposed
estrogen and/or estrogen plus progesterone) was classified as
current, past, or never use. Using FFQ and supplement use,
vitamin D insufficiency was defined as <400 IU [21], as this
was the standard used at the time of the study.TheCES-D [22]
was used to evaluate the depression status and participants
with scores above 16 were considered to have clinical levels of
depression.
2.5. Statistical Analysis. We reported the sociodemographic,
clinical, and smoking characteristics by smoking status.
Multivariable linear models estimated associations between
differences in 3-year HrQOL, ADL, and physical activity
scores and number of menopausal symptoms by baseline
smoking status. We examined univariate distributions of
each score’s differences and years since menopause to ensure
normality. Multicollinearity was ruled out by evaluating
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correlations between each potential confounder. We visually
inspected residual plots, Q-Q plots, and studentized resid-
uals. Beta coefficients and corresponding 95% confidence
intervals (CI) were derived from the adjusted models and
corrected for the number of outcomes evaluated in the study
using Bonferroni’s method.
3. Results
Of the 251 women with MS, 6% changed smoking status
from baseline measures to year 3. Nearly 9% of women were
current smokers (𝑛 = 23) and 50.2% were past smokers
(𝑛 = 126) (Table 1). Current smokers were younger than past
smokers. While 64.7% of never smokers reported ever using
alcohol, 82.6% of current and 80.2% of past smokers reported
current alcohol use. Depression varied by smoking status
with 9.1% of current smokers, 20.8% of former smokers, and
25.0% of those who never smoked experiencing depression
at baseline. All women, regardless of smoking status, had less
than 800 IU vitamin D intake per day from food, over the
counter supplements, and/or prescribed supplements. There
were no current smokerswho had less than 400 IU vitaminD;
3.2% and 4.9% of past and never smokers, respectively, had
levels below this threshold. Most women began smoking at
25 years of age or older and most reported regularly smoking
less than 15 cigarettes per day (Table 1).
Table 2 shows the changes in HrQOL from baseline to
year three of follow-up by smoking status. Age at smoking
initiation was associated with significant changes in MCS
during menopause in women with MS. PCS scores were
unchanged. No differences in change in MCS scores were
observed based on overall smoking status (current versus
past versus never smoker). Smoking pack-years were not
associated with changes in PCS or MCS. Past smokers who
reported quitting at the age of 40 or older had lower MCS
scores (adjusted 𝛽: −5.21, 95% CI: −9.3 to −1.1).
Table 3 shows the association between various definitions
of smoking and change in ADLs and physical activity from
baseline to year 3. None of the associations between ADL
change and smoking were statistically significant. Having
ever smoked was associated with changes in physical activity.
While all women’s physical activity declined, current and
former smokers were less likely to have reported reductions
in their physical activity relative to nonsmokers. For example,
women who reported never smoking experienced a decrease
of 3.66 MET task hours per week in physical activity. Former
smokers experienced a decline of 0.60 MET task hours and
current smokers a decline of 0.19 MET task hours. Relative
to women who never smoked, we observed a slower decline
in physical activity for former smokers (adjusted 𝛽: 3.76, 95%
CI: 0.00 to 7.6).
The five most prevalent menopausal symptoms reported
at baseline included joint pain/stiffness (74%), forgetfulness
(68%), difficulty in concentrating (48%), headaches (45%),
mood swings (42%), and vaginal dryness (31%). Aside from
joint pain (10%), few ranked symptoms as severe. Differences
in change in menopausal symptoms by overall smoking
status were not observed (Table 4). Changes in menopausal
symptoms were minimal over the 3-year period. None of the
variables categorizing smoking status were associated with
changes in menopausal symptoms.
4. Conclusions
To our knowledge, this is the first study to estimate the
association between smoking status and outcomes in post-
menopausal women with MS. Although the WHI-OS fol-
lowed nearly 100,000 women, only a few hundred women
noted that a physician had told them they had MS. Nearly
half of these women were past smokers, and most had ceased
at the age of 40 or older. Women with MS who began
smoking at a young age had worse mental HrQOL at year
3 than at baseline, indicating a decline in cognition during
menopause for those who began smoking at the age of 20 or
younger. Little change was observed in ADLs regardless of
smoking status. While never smokers reported a reduction
in physical activity from baseline to year 3, the reductions
in physical activity reported by current and former smokers
were less marked. The study included all postmenopausal
women even though most women experience menopausal
symptoms between the ages of 50 to 59. This may explain
why we did not observe significant changes in reports of
menopausal symptoms within the 3-year observation period.
Nevertheless, smoking status was not associatedwith changes
in menopausal symptoms.
Estimates of prevalence of smoking are much lower in
this study than in previous reports of 40% [5]. We found
that only 9% of women reported current smoking and 59%
reported that they had ever smoked. Our data are consistent
with previous findings reporting 6.3% current smokers in
the WHI-OS [23]. The findings more likely reflect the strong
decline in smoking prevalence observed in both men and
women [24]. Previous studies have linked smoking history
to worse outcomes in the MS disease process [5]. Thus,
the possibility of survival bias must be considered when
interpreting these findings. Changes in HrQOL and physical
functioning and activity measures may be more strongly
related to current smoking than past smoking. These data
must be considered in light of the unique sample. Decreases
in motor function have been noted for MS patients within 10
minutes of smoking a cigarette [25]. Current smokers were
less likely to engage in more intense physical activity over
eight years of follow-up [26]. The patterns of changes in
physical activity by smoking status may suggest that current
smokers compensate for smoking by maintaining physical
activity. This finding must be confirmed in studies with a
larger sample size. It is also possible that this association is
confounded by markers of disease severity in MS or residual
confounding by comorbid conditions. Lastly, survival bias
cannot be ruled out.
Smoking has been associated with increases in MS inci-
dence through its alterations to the blood-brain barrier [27]
by nitric oxide [28]. Younger age at smoking initiation has
been shown to be associated with an increased risk of MS
[29] and worsened prognosis from disease onset [30]. In our
study, younger age at smoking initiation was associated with
decrease in mental HrQOL. Because women who reported
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Table 1: Baseline characteristics of postmenopausal women with multiple sclerosis by smoking status in the Women’s Health Initiative
Observational Study.
Baseline characteristics Current smoker (𝑛 = 23) Past smoker (𝑛 = 126) Never smoker (𝑛 = 102)
Median (standard deviation)
Years since menopause 11.9 (7.2) 13.2 (8.4) 13.8 (9.4)
Percentages
Age
<50–59 years 65.2 48.4 46.1
60–69 years 34.8 40.5 37.3
70–79+ years 0 11.1 16.7
Race/ethnicity
Non-Hispanic white 89.5 90.0 90.5
Non-Hispanic black 10.5 6.4 2.4
Hispanic 0 3.6 3.6
Education
≤High school 13.0 16.0 16.8
Some college 47.8 36.0 36.6
≥College graduate 39.1 48.0 46.5
Have any health insurance 100 98.4 95.1
Depressed 9.1 20.8 25.0
Body mass index (kg/m2)
<18.5 (underweight) 8.7 4.8 7.8
18.5 to <25 (normal) 47.8 48.4 42.2
25 to <30 (overweight) 26.1 26.2 33.3
30+ (obese) 17.4 20.6 16.7
Alcohol use
Never drinker 0 4.0 18.6
Past drinker 17.4 15.9 16.7
Current drinker 82.6 80.2 64.7
Menopause hormone therapy
Never user 34.8 34.1 35.3
Past user 8.7 18.3 12.8
Current user 56.5 47.6 52.0
Vitamin D < 400 IU per day 0 3.2 4.9
Age started smoking (years)
<20 16.1 12.0 N/A
20 to 24 30.1 31.0 N/A
25 or older 53.8 57.1 N/A
Cigarettes smoked (per day)
<15 52.0 55.1 N/A
15 or more 48.0 44.9 N/A
Years smoked regularly
<10 4.3 27.3 N/A
10 to 29 20.2 47.6 N/A
30 to 49 63.4 23.7 N/A
50 and more 12.0 1.4 N/A
Pack-years
<10 22.2 44.9 N/A
10 to 29 35.1 31.7 N/A
30 to 49 29.2 14.5 N/A
50 or more 13.6 8.9 N/A
Age quit smoking (years)
<20 N/A 1.8 N/A
20 to 29 N/A 19.2 N/A
30 to 39 N/A 25.2 N/A
40 or older N/A 53.8 N/A
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Table 2: Association between smoking status and change in health-related quality of life measures over 3 years among postmenopausal
women with multiple sclerosis in the Women’s Health Initiative Observational Study.
Exposure
ΔPhysical component score (3-year baseline) ΔMental component score (3-year baseline)
Mean change
(standard
deviation)
𝛽-Coefficient Mean change
(standard
deviation)
𝛽-Coefficient
Crude
Adjusted1
(95% confidence
interval)
Crude
Adjusted1
(95% confidence
interval)
Smoking history
Never smokers −0.65 (8.6) Ref. Ref −0.84 (12.1) Ref. Ref.
Ever smokers −1.10 (9.5) −0.45 0.05(−3.3 to 3.4) 0.12 (11.5) 0.96
0.25
(−4.1 to 4.6)
Former smokers −0.74 (9.1) −0.10 1.67(−4.0 to 7.3) −0.25 (11.2) 0.59
−1.82
(−5.9 to 9.5)
Current smokers −2.97 (11.7) −2.33 −0.90(−6.7 to 4.9) 2.08 (13.4) 2.91
1.80
(−9.3 to 5.6)
Age started smoking
(years)
<20 −1.25 (9.6) 1.25 1.64(−7.0 to 10.3) −0.93 (11.4) −10.03
−10.45
(−19.1 to −1.8)
20 to 24 −0.58 (9.0) 1.93 2.33(−6.9 to 11.6) 0.72 (11.2) −8.37
−8.9
(−18.2 to 0.3)
25 or older −2.51 (12.3) Ref. Ref. 9.09 (12.4) Ref. Ref.
Cigarettes smoked (per
day)
<15 −1.73 (8.3) Ref. Ref. 0.71 (10.3) Ref. Ref.
15 or more −0.46 (10.7) 1.64 1.32(−2.9 to 5.5) −0.47 (12.7) −1.07
−1.16
(−6.7 to 4.4)
Years smoked regularly
<30 −1.89 (8.8) Ref. Ref. 1.12 (10.6) Ref. Ref.
30 or more −0.12 (11.1) 1.77 2.41(−2.0 to 6.8) −1.89 (13.3) −3.01
−3.29
(−9.1 to 2.6)
Number of smoking
pack-years
<10 −1.65 (8.2) Ref. Ref. −0.05 (11.2) Ref. Ref.
10 to 29 −2.31 (9.0) −0.14 −1.55(−6.0 to 2.9) 2.89 (10.1) 3.19
3.85
(−2.0 to 9.7)
30 or more 1.21 (9.9) 3.10 2.41(−4.5 to 9.3) −4.15 (13.9) −2.48
−3.49
(−12.5 to 5.5)
Age quit smoking (years)
<40 −2.94 (8.9) Ref. Ref. 1.79 (10.8) Ref. Ref.
40 or older 0.46 (9.9) 2.62 3.46(−1.3 to 8.2) −2.82 (11.9) −4.94
−4.44
(−10.8 to 1.9)
1Adjusted for the following baseline confounders: age, education, race/ethnicity, years since menopause, alcohol use, depression, and body mass index.
Bonferroni corrections applied to confidence intervals to adjust for multiple comparisons.
ever having smoked may be more likely to develop progres-
sive disease than never smokers [5], smoking cessation at
older ages may be too late to improvemental HrQOL in post-
menopause. Regardless of our specific findings, counseling
women withMS to quit smoking at the earliest age possible is
prudent.
The strengths of this study include the diverse outcomes
available in the WHI-OS. While no MS-specific measures
were collected, many of the outcomes measured (e.g., SF-36
scales, ADLs) are included in MS-specific composite mea-
sures. The WHI-OS provides data not always present in MS
registries, such as specific questions regarding menopausal
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Table 3: Association between smoking status and change in physical functioning and activity scores over 3 years among postmenopausal
women with multiple sclerosis in the Women’s Health Initiative Observational Study.
Exposure
ΔActivities of daily living (3-year baseline) ΔPhysical activity (3-year baseline)
Mean change
(standard
deviation)
𝛽-Coefficient Mean change
(standard
deviation)
𝛽-Coefficient
Crude
Adjusted1
(95% confidence
interval)
Crude
Adjusted1
(95% confidence
interval)
Smoking history
Never smokers 0.01 (0.5) Ref. Ref. −3.66 (12.3) Ref. Ref.
Ever smokers −0.02 (0.6) −0.03 −0.06(−0.3 to 0.1) −0.53 (9.8) 3.35
3.81
(0.00 to 7.6)
Former smokers −0.01 (0.53) 0.09 0.09(−0.2 to 0.4) −0.60 (10.2) −0.76
−1.06
(−7.9 to 5.7)
Current smokers −0.10 (0.62) −0.11 −0.14(−0.5 to 0.2) −0.19 (7.0) 4.00
4.72
(−2.3 to 11.7)
Age started smoking
(years)
<20 0.0 (0.6) 0.25 0.25(−0.3 to 0.8) −0.52 (9.3) −1.45
−1.09
(−11.6 to 9.4)
20 to 24 −0.03 (0.4) 0.22 0.21(−0.3 to 0.8) −0.89 (11.3) −2.06
−2.02
(−13.2 to 9.4)
25 or older 0.25 (0.5) Ref. Ref. 9.09 (12.4) Ref. Ref.
Cigarettes smoked (per
day)
<15 −0.04 (0.39) Ref. Ref. 0.14 (11.0) Ref. Ref.
15 or more 0.0 (0.7) 0.04 0.05(−0.2 to 0.3) −1.2 (8.4) −1.80
−1.58
(−6.4 to 3.3)
Years smoked regularly
<30 −0.08 (0.6) Ref. Ref. 0.04 (11.1) Ref. Ref.
30 or more 0.06 (0.5) 0.14 0.15(−0.1 to 0.4) −1.07 (6.8) −0.92
−0.93
(−6.1 to 4.2)
Number of smoking
pack- years
<10 −0.06 (0.4) Ref. Ref. −0.84 (9.6) Ref. Ref.
10 to 29 −0.02 (0.3) −0.04 −0.05(−0.3 to 0.2) −0.96 (11.8) 2.18
2.50
(−2.7 to 7.7)
30 or more −0.27 (1.2) −0.29 −0.28(−0.7 to 0.1) −0.40 (4.6) 0.83
1.76
(−6.3 to 9.9)
Age quit smoking (years)
<40 0.01 (0.5) Ref. Ref. −0.60 (10.1) Ref. Ref.
40 or older −0.10 (0.6) −0.16 −0.15(−0.4 to 0.1) −1.09 (8.8) −0.58
−0.67
(−6.2 to 4.8)
1Adjusted for the following baseline confounders: age, education, race/ethnicity, years since menopause, alcohol use, depression, and body mass index.
Bonferroni corrections applied to confidence intervals to adjust for multiple comparisons.
symptoms and the severity of the symptoms. Further, the
WHI included detailed information on the frequency and
duration of smoking (e.g., number of cigarettes per day, years
of smoking before cessation) as well as an array of potentially
confounding factors such as sociodemographics, BMI, and
vitamin D intake.
Several limitations must be kept in mind. The sample
size is small. Some may question the participant-reported
physician diagnoses of MS used in the WHI. A validation
study of self-reported diagnosis ofMS in theNorth American
Research Committee on MS registry showed a 98.79% sensi-
tivity of self-report when compared to chart review and/or
Multiple Sclerosis International 7
Table 4: Association between smoking status and change inmenopausal symptoms over 3 years among postmenopausal womenwithmultiple
sclerosis in the Women’s Health Initiative Observational Study.
Exposure
ΔMenopausal symptoms (3-year baseline)
Mean change
(standard deviation)
𝛽-Coefficient
Crude
Adjusted1
(95% confidence
interval)
Smoking history
Never smokers 0.15 (1.5) Ref. Ref.
Ever smokers 0.07 (1.3) −0.07 −0.06(−0.5 to 0.4)
Former smokers 0.06 (1.3) −0.12 −0.09(−0.9 to 0.7)
Current smokers 0.17 (1.5) 0.03 0.01(−0.8 to 0.9)
Age started smoking (years)
<20 0.08 (1.5) 0.37 0.55(−0.8 to 1.9)
20 to 24 0.00 (0.9) 0.25 0.37(−1.1 to 1.8)
25 or older −0.25 (1.4) Ref. Ref.
Cigarettes smoked (per day)
<15 0.12 (1.1) Ref. Ref.
15 or more 0.03 (1.6) −0.09 −0.09(−0.7 to 0.5)
Years smoked regularly
<30 0.03 (1.2) Ref. Ref.
30 or more 0.14 (1.6) 0.11 0.10(−0.6 to 0.7)
Number of smoking pack-years
<10 0.09 (1.4) Ref. Ref.
10 to 29 0.25 (1.2) 0.12 0.07(−0.6 to 0.7)
30 or more −0.12 (1.7) −0.99 −0.87(−1.9 to −0.1)
Age quit smoking (years)
<40 0.12 (1.2) Ref. Ref.
40 or older 0.03 (1.4) 0.05 0.02(−0.7 to 0.7)
1Adjusted for the following baseline confounders: age, education, race/ethnicity, years since menopause, alcohol use, depression, and body mass index.
Bonferroni corrections applied to confidence intervals to adjust for multiple comparisons.
physician report [31]. Thus, we were comfortable with our
decision to use the self-reported diagnosis of MS available in
the WHI-OS.
This study evaluated the effects of smoking on HrQOL
and physical measures in postmenopausal women with MS.
Despite the large size of theWHI-OS,wehad a relatively small
sample of women with MS in our study. As these women
were healthier than the general population and few were
current smokers, effects were not found for all outcomes by
all smoking frequencies or duration. Nevertheless, women
withMS should be encouraged to quit smoking at the earliest
age possible. Patterns were found pointing to an association
between initiation of smoking at younger ages and decline
of mental HrQOL during menopause. Longitudinal studies
of age at smoking initiation and relevant outcomes for older
women with MS are needed.
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